文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核病高流行国家耐药监测的基因测序:多国人群为基础的监测研究

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
PubMed 文献 · Lancet Infect Dis · 2018-03-21

在七个结核病高流行国家开展人群水平调查,纳入2009年11月至2014年5月登记的7094例结核病患者分离株,以表型药敏试验为参照评估基因测序预测耐药的准确性。基因测序预测耐药的合并敏感度因药物而异,rpoB(利福平耐药)为91%(95%CI 87-94),pncA(吡嗪酰胺耐药)为54%(39-68);多数药物和多数地区基因测序与表型试验估计的耐药患病率高度重叠。作者认为基因测序可作为耐药监测的有价值工具,但广泛采用前需标准化DNA提取方法、记录与报告命名及数据解读。

要点

  • 基因测序预测利福平耐药(rpoB)合并敏感度91%(95%CI 87-94)。
  • 基因测序预测吡嗪酰胺耐药(pncA)合并敏感度54%(95%CI 39-68)。
  • 多数药物和地区基因测序与表型试验估计的耐药患病率高度重叠。

核心结论

  • 基因测序可作为结核病耐药监测的有价值工具,为资源贫乏国家监测结核病耐药提供新机会。
  • 在广泛用于监测目的之前,需要标准化DNA提取方法、记录与报告命名及数据解读。

研究设计与样本

  • 在七个国家(阿塞拜疆、孟加拉国、白俄罗斯、巴基斯坦、菲律宾、南非和乌克兰)的医院和诊所开展人群水平调查。
  • 评估基因测序估计结核分枝杆菌分离株对利福平、异烟肼、氧氟沙星、莫西沙星、吡嗪酰胺、卡那霉素、阿米卡星和卷曲霉素耐药性的作用。
  • 对每种药物,通过比较基因测序测得的校正耐药患病率与表型试验确定的真实耐药患病率来评估基因测序的准确性。
  • 分离株取自2009年11月至2014年5月期间登记的7094例结核病患者。

主要发现

  • 在所有结核病例中,基因测序预测耐药的总体合并敏感度:rpoB(利福平耐药)为91%(95%CI 87-94)。
  • katG、inhA和fabG启动子联合(异烟肼耐药)的合并敏感度为86%(95%CI 74-93)。
  • pncA(吡嗪酰胺耐药)的合并敏感度为54%(95%CI 39-68)。
  • gyrA和gyrB联合(氧氟沙星耐药)的合并敏感度为85%(95%CI 77-91);gyrA和gyrB联合(莫西沙星耐药)的合并敏感度为88%(95%CI 81-92)。
  • 对几乎所有药物和多数地区,基因测序估计的耐药患病率与表型试验估计的患病率高度重叠。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In many countries, regular monitoring of the emergence of resistance to anti-tuberculosis drugs is hampered by the limitations of phenotypic testing for drug susceptibility. We therefore evaluated the use of genetic sequencing for surveillance of drug resistance in tuberculosis. METHODS: Population-level surveys were done in hospitals and clinics in seven countries (Azerbaijan, Bangladesh, Belarus, Pakistan, Philippines, South Africa, and Ukraine) to evaluate the use of genetic sequencing to estimate the resistance of Mycobacterium tuberculosis isolates to rifampicin, isoniazid, ofloxacin, moxifloxacin, pyrazinamide, kanamycin, amikacin, and capreomycin. For each drug, we assessed the accuracy of genetic sequencing by a comparison of the adjusted prevalence of resistance, measured by genetic sequencing, with the true prevalence of resistance, determined by phenotypic testing. FINDINGS: Isolates were taken from 7094 patients with tuberculosis who were enrolled in the study between November, 2009, and May, 2014. In all tuberculosis cases, the overall pooled sensitivity values for predicting resistance by genetic sequencing were 91% (95% CI 87-94) for rpoB (rifampicin resistance), 86% (74-93) for katG, inhA, and fabG promoter combined (isoniazid resistance), 54% (39-68) for pncA (pyrazinamide resistance), 85% (77-91) for gyrA and gyrB combined (ofloxacin resistance), and 88% (81-92) for gyrA and gyrB combined (moxifloxacin resistance). For nearly all drugs and in most settings, there was a large overlap in the estimated prevalence of drug resistance by genetic sequencing and the estimated prevalence by phenotypic testing. INTERPRETATION: Genetic sequencing can be a valuable tool for surveillance of drug resistance, providing new opportunities to monitor drug resistance in tuberculosis in resource-poor countries. Before its widespread adoption for surveillance purposes, there is a need to standardise DNA extraction methods, recording and reporting nomenclature, and data interpretation. FUNDING: Bill & Melinda Gates Foundation, United States Agency for International Development, Global Alliance for Tuberculosis Drug Development.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zignol M, Cabibbe AM, Dean AS, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018. PMID: 29574065. doi:10.1016/S1473-3099(18)30073-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。